Roceld Rojo
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- Nosocomial Infections in ICU 4
- Intensive Care Unit Cognitive Disorders 2
-
- COVID-19 Clinical Research Studies 7
- Infection Control in Healthcare 2
- Journals
- JAMA (8 papers)Intensive Care Medicine (5 papers)Nature (4 papers)JAMA Network Open (1 paper)Intensive Care Medicine Experimental (1 paper)
- Partner nations
- AustraliaUnited KingdomUnited States
In The Last Decade
Roceld Rojo
22 papers receiving 1.9k citations
Roceld Rojo's Hit Papers
Peers
Comparison fields: 5 of 94
- Infectious Diseases 870
- Applied Microbiology and Biotechnology 42
- Genetics 504
- Critical Care and Intensive Care Medicine 64
- Molecular Medicine 61
Countries citing papers authored by Roceld Rojo
This map shows the geographic impact of Roceld Rojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roceld Rojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roceld Rojo more than expected).
Fields of papers citing papers by Roceld Rojo
This network shows the impact of papers produced by Roceld Rojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roceld Rojo. The network helps show where Roceld Rojo may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Mapping the human genetic architecture of COVID-19 Hit paper breakdown → | 2021 | 656 |
| 2 | Whole-genome sequencing reveals host factors underlying critical COVID-19 Hit paper breakdown → | 2022 | 233 |
| 3 | Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study Hit paper breakdown → | 2023 | 168 |
| 4 | 2021 | 166 | |
| 5 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 6 | 2022 | 105 | |
| 7 | 2022 | 100 | |
| 8 | Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis Hit paper breakdown → | 2024 | 94 |
| 9 | 2021 | 72 | |
| 10 | 2023 | 62 | |
| 11 | 2023 | 60 | |
| 12 | 2023 | 46 | |
| 13 | 2023 | 34 | |
| 14 | Dexmedetomidine- or Clonidine-Based Sedation Compared With Propofol in Critically Ill Patients Hit paper breakdown → | 2025 | 17 |
| 15 | 2024 | 9 | |
| 16 | 2024 | 8 | |
| 17 | 2025 | 8 | |
| 18 | 2024 | 3 | |
| 19 | 2026 | 3 | |
| 20 | 2025 | 1 |
About Roceld Rojo
Roceld Rojo is a scholar working on Critical Care and Intensive Care Medicine, Infectious Diseases, Genetics, Applied Microbiology and Biotechnology and Epidemiology, having authored 23 papers that have together received 2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Genetic Associations and Epidemiology (6 papers), Sepsis Diagnosis and Treatment (5 papers), Nosocomial Infections in ICU (4 papers), Intensive Care Unit Cognitive Disorders (2 papers), Anesthesia and Sedative Agents (2 papers), Infection Control in Healthcare (2 papers) and Antibiotic Use and Resistance (2 papers). The work is most often cited by research in Infectious Diseases (870 citations), Applied Microbiology and Biotechnology (42 citations), Genetics (504 citations), Critical Care and Intensive Care Medicine (64 citations) and Molecular Medicine (61 citations). Roceld Rojo has collaborated with scholars based in Australia, United Kingdom and United States. Their work appears in journals such as JAMA, Intensive Care Medicine, Nature, JAMA Network Open and Intensive Care Medicine Experimental.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.